Adherencia a las recomendaciones de tratamiento de la guía colombiana de neumonía adquirida en la comunidad del 2013 y su relación con mortalidad y estancia hospitalaria, en un hospital de tercer nivel de Bogotá D.C.
dc.contributor.advisor | Toledo Arenas, José Daniel | |
dc.contributor.author | Rojas Durán, Angélica María | |
dc.contributor.author | Gallego Cardona, Laura | |
dc.contributor.author | Ordoñez Cardales, Jorge Alberto | |
dc.contributor.author | Russi Lozano, Jorge Andrés | |
dc.contributor.author | Vergara Vela, Erika Paola | |
dc.date.accessioned | 2019-11-20T17:33:42Z | |
dc.date.available | 2019-11-20T17:33:42Z | |
dc.date.issued | 2019 | |
dc.description.abstract | La NAC es una de las infecciones más frecuentes, entre el 20 - 42% de los casos requieren atención hospitalaria y de estos del 10-30% ingresan a UCI, asociándose con altas tasas de morbilidad y mortalidad. El manejo de la NAC es de controversia mundial, razón por la cual se ha promovido la elaboración de guías y recomendaciones de las diferentes asociaciones científicas. Objetivo Determinar la adherencia a las recomendaciones de tratamiento de la guía de “Práctica Clínica para el Diagnóstico, Tratamiento y Prevención de la NAC del 2013”, su relación con mortalidad y estancia hospitalaria, en un hospital III nivel de Bogotá entre junio 2013 - marzo 2015. Estudio de tipo observacional, retrospectivo, de corte transversal con componente analítico. Se incluyeron adultos inmunocompetentes con diagnóstico de NAC hospitalizados entre junio 2013 - marzo 2015. El diagnostico de neumonía fue confirmado por criterios clínicos y radiológicos descritos en la historia clínica. Se utilizó estadística descriptiva para calcular las medidas de tendencia central. Se utilizó el test de la t de Student para analizar diferencias de las variables cuantitativas y la prueba de Pearson para analizar la relación entre los datos cualitativos, para aquellos con valores esperados menores a 5 se aplicó test exacto de Fisher y se realizó un modelo de regresión logística. Se incluyeron 103 pacientes con NAC, con una adherencia a la guía del 56.3%. La estancia hospitalaria tanto para los no adherentes como para los adherentes fue de 11.1 +/- 6.9 días, mientras que estancia en UCI para los que no siguieron la indicación de la guía fue de 6. 4 +/- 5.5 Vs 5.1 +/-3.4 días en los que, si se siguieron las recomendaciones de la guía, a pesar de un ligero menor número de días en este último, no hubo diferencias estadísticamente significativas. En cuanto a la clasificación por CURB-65, lo más adherentes a la guía son los CURB-65 de mayor gravedad y se encontró la no adherencia a la guía como factor de riesgo para mortalidad en nuestros pacientes con NAC, con un OR: 3.3 (IC: 0.82-13.8). Hay una baja adherencia a la guía de NAC en nuestro hospital, en relación a la epidemiologia mundial, pero se encuentra por muy por encima de la adherencia encontrada en estudios colombianos. La adherencia a la guía se asoció con una tendencia a menor estancia hospitalaria, estancia en UCI pero con una diferencia estadísticamente no significativa. La no adherencia a la guía de NAC se asoció a mayor mortalidad. | spa |
dc.description.abstractenglish | The community-acquired pneumonia (CAP) is one of the most common infections, 20-42% of cases require hospital care and 10-30% of those admitted to ICU, associated with high morbidity and mortality. The management of CAP is world controversy, why has promoted the development of guidelines and recommendations of various scientific associations. Determine adherence to the treatment recommendations the guidance of "Clinical Practice for the Diagnosis, Treatment and Prevention of CAP 2013", its relation to mortality and Hospital length of stay, in a hospital III level in Bogotá between June 2013 - March 2015. This is an observational, retrospective, cross-sectional study with an analytical component. We included immunocompetent adults diagnosed with CAP, hospitalized between June 2013-March 2015. The diagnosis of pneumonia was confirmed by clinical and radiological criteria. We use descriptive statistics to calculate measures of central tendency. The t test of Student was used to analyze quantitative difference variables and Pearson's test to analyze the relationship between qualitative data, Fisher's exact test applies to expected values below 5 and finally a logistic regression model was applied. We included 103 patients with CAP, we found adherence to the guidance of 56.3%. The Hospital length of stay for the two groups, non-adherent and adherent was 11.1 +/- 6.9 days, while ICU stay for those were non-adherent to the guide was 6. 4 +/- 5.5 vs. 5.1 +/- 3.4 days in which they were adhered to the recommendations of the guide, although there is a lower number of days in adherent patients, there were no statistically significant differences. Regarding the classification by CURB-65, the most adherents to the guide the CURB-65 are highest severity. We find that no adherence to the guide is a risk factor for mortality in our patients with CAP, with an OR: 3.3 (CI: 0.82-13.8). There is a low adherence to the guidance of CAP in relation to global publications but good adherence to guidelines compared with the findings in the Colombian epidemiology. The guideline adherence was associated with shorter hospital stay, ICU stay and reduced in hospital mortality but with a difference statistically non-significant. Non-adherence to the guidance of NAC is a risk factor for mortality. | eng |
dc.description.degreelevel | Pregrado | spa |
dc.description.degreename | Especialista en Medicina Interna | spa |
dc.format.mimetype | application/pdf | |
dc.identifier.instname | instname:Universidad El Bosque | spa |
dc.identifier.reponame | reponame:Repositorio Institucional Universidad El Bosque | spa |
dc.identifier.repourl | repourl:https://repositorio.unbosque.edu.co | |
dc.identifier.uri | https://hdl.handle.net/20.500.12495/1863 | |
dc.language.iso | spa | |
dc.publisher.faculty | Facultad de Medicina | spa |
dc.publisher.grantor | Universidad El Bosque | spa |
dc.publisher.program | Especialización en medicina interna | spa |
dc.relation.references | Wunderink Richard G., Waterer Grant W. Community-Acquired Pneumonia. N Engl J Med 2014;370:543-51. | spa |
dc.relation.references | The top 10 causes of death. Geneva: World Health Organization, 2013 (https://www.who.int/mediacentre/factsheets/fs310/en/index.html) | spa |
dc.relation.references | Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with Community-acquired pneumonia. A meta-analysis. JAMA 1996; 275(2):134–41. | spa |
dc.relation.references | Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820-837. | spa |
dc.relation.references | Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002; 166:717-23. | spa |
dc.relation.references | Frei Christopher R., Restrepo Marcos I., Mortensen Eric M., Burgess David S. Impact of Guideline-Concordant Empiric Antibiotic Therapy in Community-Acquired Pneumonia. Am J Med. 2004; 117:726-731. | spa |
dc.relation.references | Mortensen EM, Restrepo M, Anzueto A, Pugh J. Effects of guideline concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. The American Journal of Medicine. 2006. Vol 119, No 10. | spa |
dc.relation.references | Yealy DM, Auble TE, Stone RA, Lave JR, Meehan TP, Graff LG, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med. 2005;143(12):881-94. PMid:16365469 | spa |
dc.relation.references | Silveira Carla, Ferreira Cid Sergio, et al; Adherence to guidelines and its impact on outcomes in patients hospitalized with community-acquired pneumonia at a university hospital. J Bras Pneumol. 2012;38(2):148-157 | spa |
dc.relation.references | Machado-Alba J, Isaza-Martínez B, Sepulveda-Marín M, Rivera-Palacios A, Ceballos S. Nivel de adherencia a la guía de atención de neumonía adquirida en la comunidad en el Hospital Universitario San Jorge de Pereira, Colombia. Rev Med Risa. 2012; 18(2): 135-9 | spa |
dc.relation.references | . Montúfar Franco Eduardo, Varón Fabio Andrés, Giraldo Luis Fernando, Sáenz Óscar Alberto, Ortiz Guillermo, et al; Recomendaciones para el diagnóstico, tratamiento y prevención de la neumonía adquirida en la comunidad en adulto inmunocompetentes. Infectio. 2013;17 (Supl 1): 1-38 | spa |
dc.relation.references | Alcon A, Fabregas N, Torres A. Pathophysiology of Pneumonia. Clinical Chest Med 26, 39 – 46, 2005. | spa |
dc.relation.references | Dirección Seccional de Salud de Antioquia. Estadísticas, diez primeras causas de morbilidad y mortalidad por hospitalización y consulta. Julio de 2012. Disponible en: https://www.dssa.gov.co/index.php/estadisticas/morbilidad | spa |
dc.relation.references | Luna CM, Famiglietti A, Absi R, Videla AJ, Nogueira FJ, Fuenzalida AD, et al. Community-acquired pneumonia: etiology, epidemiology and outcome at a teaching hospital in Argentina. Chest. 2000; 118:1344-54. | spa |
dc.relation.references | Vélez L, Rueda Z, Aguilar Y, Rojas E, Arroyave M, Segura A, et al. NAC en Medellín, 2005-2006: alta frecuencia de bacterias atípicas y virus respiratorios. Rev Colomb Neumol. 2007;19:154 | spa |
dc.relation.references | Caballero A, Polanía E, Gordillo M, Martínez O, Torrado E, et al. Agentes etiológicos de Neumonía Adquirida en Comunidad (NAC) en pacientes adultos inmunocompetentes que consultan al servicio de urgencias de la Clínica Reina Sofía, Bogotá, 2006-2007. Rev Médica Sanitas. 2010; 13:8-18. | spa |
dc.relation.references | Díaz A, Barria P, Niederman M, Restrepo M, Dreyse J, Fuentes G, et al. Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest. 2007; 131:779-87. | spa |
dc.relation.references | Smayevsky J, López H, Di Chiara M, Scarano S, Lanza A, Vilches V, et al. Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection. Diag Microbiol Infect Dis. 2000; 37:261-4. | spa |
dc.relation.references | Mont far E, ueda V, Correa LT, Véle LA, Ortega , Ortega , Segura A, Gon ále G. Características y comportamiento de la neumonía adquirida en la comunidad en adultos mayores hospitali ados en el Valle de Aburrá, Antioquia. Infectio 200 ; 10 2 : 138. | spa |
dc.relation.references | Chaparro C, Ortega , Torres CA, Giraldo . Neumonía adquirida en la comunidad. ev Colomb Neumol 1989; 1:19-24. | spa |
dc.relation.references | Lim W. S, Baudouin S. V, George R C, Hill A T, Jamieson C, Jeune I Le, Macfarlane J T, Read R C, Roberts H J, Levy M L, Wani M, Woodhead M A. British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64. | spa |
dc.relation.references | Fine MJ, Auble TE et al. A prediction rule to identify low risk patients with community acquired pneumonia. N Engl J Med 1997; (336):243-250. | spa |
dc.relation.references | Ewig S, oux A de, Bauer T, Garcıa E, Mensa , Niederman M, Torres A. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004;59:421–427. | spa |
dc.relation.references | Lim W S, Van der Eerden M M, Laing R, Boersma W G, Karalus N, Town G I, Lewis S A, Macfarlane J T. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377–382. | spa |
dc.relation.references | ATS/IDSA; Consensus Guidelines on the management of community acquired pneumonia in adults. Clinics Infectious Diseases 2007; 44: S27-S72 | spa |
dc.relation.references | Phua J, See KC, Chan YH, et al. Validation and clinical implications of the IDSA/ ATS minor criteria for severe community-acquired pneumonia. Thorax 2009; 64:598–603. | spa |
dc.relation.references | Anderson G, Esmonde TS, Coles S, Macklin J, Carnegie C. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother. 1991; 27 Suppl A: 117-24. | spa |
dc.relation.references | Chien SM, Pichotta P, Siepman N, Chan CK. Treatment of community-acquired pneumonia. A multicenter, doubleblind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group. Chest. 1993;103:697-701 | spa |
dc.relation.references | Grupo de trabajo de la Asociación Latinoamericana del Tórax (ALAT). Actualización de las recomendaciones ALAT sobre la neumonía adquirida en la comunidad. Arch Bronconeumol 2004;40(8):364-74 | spa |
dc.relation.references | Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164:637-44. | spa |
dc.relation.references | Garin Nicolas, Genné Daniel, Carballo Sebastian, Chuard Christian, Eich Gerhardt, Hugli Olivier. Et al. β-Lactam Monotherapy vs β-Lactam–Macrolide Combination Treatment in Moderately Severe Community-Acquired Pneumonia. A Randomized Noninferiority Trial. JAMA Intern Med. 2014; 174(12):1894-1901. | spa |
dc.relation.references | Tessmer A, , Welte T., Martus P., Schnoor M., Marre R., Suttorp N. Impact of intravenous b-lactam/macrolide versus b-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. Journal of Antimicrobial Chemotherapy (2009) 63, 1025–1033. | spa |
dc.relation.references | Emmet O'Brien M, Restrepo MI, Martin-Loeches I. Update on the combination effect of macrolide antibiotics in community-acquired pneumonia. Respir Investig 2015 Sep;53(5):201-9. | spa |
dc.relation.references | Dellinger P, Levy M, Rhodes A, Annane D. Survivind Sepsis Campaign Guidelines Committee, Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Crit Care Med. 2013; 41:580-637. | spa |
dc.relation.references | Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-96. | spa |
dc.relation.references | Gomez Carlos Hernando, Perilla Ana Maria, Gonzalez camilo, Valderrama Sandra Liliana, et al. Neumonía necrosante por Staphylococcus aureus extrahospitalario resistente a la meticilina: reporte de dos casos en Colombia. Biomédica 2009;29:523-30 | spa |
dc.relation.references | Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methycillin-resistant Staphylococcus aureus. J Infect Dis. 2007; 195:202-11. | spa |
dc.relation.references | Gillet Yves, Vanhems Philippe, Lina Gerard, et. al. Factors Predicting Mortality in Necrotizing Community-Acquired Pneumonia Caused by Staphylococcus aureus Containing Panton-Valentine Leukocidin. Clinical Infectious Diseases 2007; 45:315–21 | spa |
dc.relation.references | Arancibia Francisco, Bauer Torsten T, Ewig Santiago, Mensa Josep, Gonzalez Julia, Niederman Michael S Torres Antoni. Community-Acquired Pneumonia Due to Gram-Negative Bacteria and Pseudomonas aeruginosa Incidence, Risk, and Prognosis. Arch Intern Med. 2002;162(16):1849-1858. | spa |
dc.relation.references | Isturiz R, Luna C, Ramírez J. Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis.2010 | spa |
dc.relation.references | Menendez R, Torres A, Reyes S, Zalacain R, Capelastegui A, et al. Compliance with Guidelines-Recommended Processes in Pneumonia: Impact of Health Status and Initial Signs. PLoS One 2012;7(5):e37570. | spa |
dc.relation.references | Dean NC, Bateman KA, Donnelly SM, Silver MP, Snow GL, et al. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest (2006) 130(3): 794–9 | spa |
dc.relation.references | Garcia VE, Mensa J, Martinez JA et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a b-lactam agent versus a b-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005. | spa |
dc.relation.references | Montúfar FE, Correa LT, Rueda ZV, Ortega H, Ortega J, Segura A, et al. Impacto del antígeno urinario de neumococo en el diagnostico etiológico de NAC. Infectio. 2006; 10:106-7. | spa |
dc.relation.references | Arnold Forest, LaJoie A. Scott, Brock Guy N., Peyrani Paula, Rello Jordi, Menendez Rosario, Lopardo Gustavo, Torres Antoni. Improving Outcomes in Elderly Patients With Community-Acquired Pneumonia by Adhering to National Guidelines. Arch Intern Med. 2009;169(16):1515-1524 | spa |
dc.relation.references | Montúfar FE, Correa LT, Rueda ZV, Ortega H, Ortega J, Segura A, et al. Características de la Neumonía Adquirida en Comunidad (NAC) por S. pneumoniae, con y sin bacteremia en el Valle de Aburrá, 2005-2006. ACMI, Cartagena, octubre de 2006. | spa |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | * |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
dc.rights.accessrights | https://purl.org/coar/access_right/c_abf2 | |
dc.rights.creativecommons | 2016 | |
dc.rights.local | Acceso abierto | spa |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject.nlm | WB 115 | spa |
dc.title | Adherencia a las recomendaciones de tratamiento de la guía colombiana de neumonía adquirida en la comunidad del 2013 y su relación con mortalidad y estancia hospitalaria, en un hospital de tercer nivel de Bogotá D.C. | spa |
dc.title.translated | Adhesion to treatment recommendations Colombian guide community-acquired pneumonia 2013 and its relation with mortality and length of stay in a third level hospital in Bogotá D.C. | spa |
dc.type.coar | https://purl.org/coar/resource_type/c_7a1f | spa |
dc.type.driver | info:eu-repo/semantics/bachelorThesis | spa |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
dc.type.local | Trabajo de grado | spa |
dc.type.local | Tesis/Trabajo de grado - Monografía - Doctorado | spa |
Archivos
Bloque original
1 - 2 de 2
Cargando...
- Nombre:
- Rojas_Duran_Angelica_Maria_2016.pdf
- Tamaño:
- 968.6 KB
- Formato:
- Adobe Portable Document Format
- Descripción:
No hay miniatura disponible
- Nombre:
- Rojas_Duran_Angélica_Maria_2016_Carta_autorización.pdf
- Tamaño:
- 1.87 MB
- Formato:
- Adobe Portable Document Format
- Descripción:
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 1.71 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: